Jiang Liyu, Jing Chuyu, Kong Xiaoli, Li Xiaoyan, Ma Tingting, Huo Qiang, Chen Junfei, Wang Xiaoting, Yang Qifeng
Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China; Pathology Tissue Bank, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Oncol Lett. 2016 Aug;12(2):1448-1454. doi: 10.3892/ol.2016.4754. Epub 2016 Jun 21.
In China, the adjuvant epirubicin and docetaxel (ED) regimen is widely used as a substitute for the epirubicin and cyclophosphamide followed by docetaxel (EC-D) regimen in patients with operable breast cancer. However, their equivalence has not yet been demonstrated. This retrospective study compared these two adjuvant regimens as regards feasibility, safety and efficacy. Data on consecutive patients who received either ED (70/75 mg/m every 3 weeks for 6 cycles) or EC-D (70/600 mg/m epirubicin/cyclophosphamide followed by 75 mg/m docetaxel every 3 weeks for 4 cycles each) as their adjuvant chemotherapy in our center from January 2009 to January 2014, were analyzed. A total of 374 patients was enrolled, among whom 250 patients received the ED regimen, and 124 patients received the EC-D regimen. The overall median follow-up time was 38.6 months. In total, 90 and 94.4% of patients in the ED and EC-D groups, respectively, completed full cycles of chemotherapy (P=0.174). There was no difference in efficacy in terms of disease-free survival (DFS) and overall survival (OS) (DFS, P=0.919; OS, P=0.069). The incidence of neutropenia in the ED group was similar to that in the EC-D group (81.2 vs. 78.9%, P=0.660) with a similar utilization rate of granulocyte-colony stimulating factor (G-CSF; 76.9 vs. 75.2%, P=0.850). However, grade 3/4 gastrointestinal reactions were more frequently observed in the patients who received the EC-D regimen (42.0 vs. 29.2%, P=0.058). The findings of our study indicate that with similar feasibility, safety and mid-term efficacy, the adjuvant ED regimen for 6 cycles may be an alternative to the EC-D regimen in operable breast cancer.
在中国，对于可手术乳腺癌患者，辅助性表柔比星联合多西他赛（ED）方案被广泛用作表柔比星联合环磷酰胺序贯多西他赛（EC-D）方案的替代方案。然而，两者的等效性尚未得到证实。这项回顾性研究比较了这两种辅助方案在可行性、安全性和疗效方面的差异。分析了2009年1月至2014年1月在本中心接受ED方案（每3周70/75mg/m²，共6个周期）或EC-D方案（表柔比星/环磷酰胺70/600mg/m²，随后每3周75mg/m²多西他赛，各4个周期）作为辅助化疗的连续患者的数据。共纳入374例患者，其中250例接受ED方案，124例接受EC-D方案。总体中位随访时间为38.6个月。ED组和EC-D组分别有90%和94.4%的患者完成了完整化疗周期（P=0.174）。在无病生存期（DFS）和总生存期（OS）方面，疗效无差异（DFS，P=0.919；OS，P=0.069）。ED组中性粒细胞减少的发生率与EC-D组相似（81.2%对78.9%，P=0.660），粒细胞集落刺激因子（G-CSF）的使用率也相似（76.9%对75.2%，P=0.850）。然而，接受EC-D方案的患者中3/4级胃肠道反应更为常见（42.0%对29.2%，P=0.058）。我们的研究结果表明，对于可手术乳腺癌，6周期的辅助ED方案在可行性、安全性和中期疗效方面相似，可能是EC-D方案的替代方案。
